Biochemical Safety of SBRT to Multiple Intrahepatic Lesions for Hepatocellular Carcinoma
Jacob Hall,Andrew Moon,Michael Young,Xianming Tan,Rami Darawsheh,Flora Danquah,Joel Tepper,Ted Yanagihara
DOI: https://doi.org/10.2147/jhc.s447025
2024-03-05
Journal of Hepatocellular Carcinoma
Abstract:Jacob T Hall, 1 Andrew M Moon, 2, 3 Michael Young, 1 Xianming Tan, 3, 4 Rami Darawsheh, 5 Flora Danquah, 3 Joel E Tepper, 1, 3 Ted K Yanagihara 1, 3 1 Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, NC, USA; 2 Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; 3 Lineberger Comprehensive Cancer Center, University of North Carolina Hospitals, Chapel Hill, NC, USA; 4 Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA; 5 University of North Carolina School of Medicine, Chapel Hill, NC, USA Correspondence: Ted K Yanagihara, Department of Radiation Oncology, 101 Manning Drive CB &num7512, Chapel Hill, NC, 27514, USA, Tel +1-984-974-0400, Email Background: We aim to better characterize stereotactic body radiation therapy (SBRT)-related hepatic biochemical toxicity in patients with multiple intrahepatic lesions from hepatocellular carcinoma (HCC). Methods: We conducted a retrospective analysis of patients with HCC who underwent SBRT for 2 or more synchronous or metachronous liver lesions. We collected patient characteristics and dosimetric data (mean liver dose [MLD], cumulative effective volume [Veff], cumulative volume of liver receiving 15 Gy [V15Gy], and cumulative planning target volume [PTV]) along with liver-related toxicity (measured by albumin-bilirubin [ALBI] and Child–Pugh [CP] scores). A linear mixed-effects model was used to assess the effect of multi-target SBRT on changes in ALBI. Results: There were 25 patients and 56 lesions with median follow-up of 29 months. Eleven patients had synchronous lesions, and 14 had recurrent lesions treated with separate SBRT courses. Among those receiving multiple SBRT courses, there were 7 lesions with overlap of V15Gy (median V15Gy overlap: 35 mL, range: 0.5– 388 mL). There was no association between cumulative MLD, Veff, V15Gy, or PTV and change in ALBI. Four of 25 patients experienced non-classic radiation-induced liver disease (RILD), due to an increase of CP score by ≥ 2 points 3 to 6 months after SBRT. Sixteen of 25 patients experienced an increase in ALBI grade by 1 or more points 3 to 6 months after SBRT. Comparing the groups that received SBRT in a single course versus multiple courses revealed no statistically significant differences in liver toxicity. Conclusion: Liver SBRT for multiple lesions in a single or in separate courses is feasible and with acceptable risk of hepatotoxicity. Prospective studies with a larger cohort are needed to better characterize safety in this population. Keywords: HCC, SBRT, reirradiation, multi-site, toxicity The incidence of HCC has steadily increased over the last 20 years or more. 1 Radiation therapy was initially used for palliation and has historically had a limited role in the management of HCC, largely because early experience using older radiation techniques resulted in excessive normal tissue toxicity, and prospective data are sparse. 2–4 Over the last several decades, rigorous studies have investigated liver tolerance to irradiation and defined safe treatment parameters. 5,6 This body of work, along with improvements in radiotherapy delivery techniques, such as SBRT, have led to numerous retrospective and prospective series demonstrating excellent disease control with a favorable toxicity profile. Despite excellent local control (LC) in the range of 75–90% beyond two years, 7–11 patients with localized HCC treated with SBRT, or other focal therapies, will often have recurrence within the liver, and many present with multiple lesions over time. 12–14 Additionally, 80–90% of patients with HCC have clinically significant underlying liver disease, 15 and functional liver reserve is an important consideration when selecting the optimal locoregional therapy for recurrent HCC. Furthermore, radiation tolerance of the liver is known to be worse in patients with underlying cirrhosis compared to those without cirrhosis. 16,17 Re-irradiation poses unique challenges, primarily due to a poor radiobiological understanding of how the liver recovers from prior radiation dose and how volumetric constraints may need to be modified based on prior treatment. 18 Data evaluating the efficacy and safety of SBRT in cirrhotic patients who have been previously irradiated or have multiple sites within the liver being irradiated simultaneously are very limited. 19–26 To our knowledge, only two studies 19,20 have evaluated hepatotoxicity in th -Abstract Truncated-
oncology